表阿霉素联奥沙利铂卡培他滨eox一线治疗晚期胃癌的临床研究分析.ppt

2020/5/9 FLO vs FLP Al-Batran S, et al. J Clin Oncol 2008; 26 TTF PFS OS 2020/5/9 疗效讨论 : 2. capecitabine Ajani, et al. Cancer 2006; 107 2020/5/9 Authors Regimens ORR TTP OS Hoff PM, (650 pats) X vs bolus 5- FU/LV 24.8 vs 15.5% （ p= 0.005 ） 4.3 vs 4.7m (p=0.72) 12.5 vs 13.3m (p=0.974) Van Cutsem E, (602 pats) X vs bolus 5- FU/LV 18.9 vs 15.0% 5.2 vs 4.7m (p=0.65) 13.2 vs 12.1m (p=0.33) Porschen R, (474 pats) X+O vs FUFOX 48 vs 54% 7.1 vs 8.0m (0.117) 16.8 vs 18.8m (p=0.26) Dí az-Rubio E, (348 pats) X+O vs FUFOX 37 vs 46% (p=0.54) 8.9 vs 9.5m (0.153) 18.1 vs 20.8m (0.145) Cassidy J (2034 pats) X+O vs FOLFOX 47 vs 48% 8.0 vs 8.5m 19.8 vs 19.6m Capecitabine alone or in combination in advanced CRC 2020/5/9 表阿霉素联奥沙利铂、卡培他滨 (EOX) 一线治疗晚期胃癌的临床研究分析 南昌大学一附院肿瘤科 项晓军 2020/5/9 Chemotheray VS BSC Wagner AD, et al. J Clin Oncol 2006; 24 2020/5/9 combination vs single agent Wagner AD, et al. J Clin Oncol 2006; 24 2020/5/9 Drug combinations ? FAM FU, doxorubicin, mitomycins ? FAMTX FU, doxorubicin, methotrexate(high dose) ? EAP etopside, doxorubicin, cisplatin ? PELF epirubicin, cisplatin, leucovorin, FU(bolus) ? ECF epirubicin, cisplatin, FU(infusional) ? CF cisplatin, FU ? IC irinotecan, FU, leucovorin ? TC docetaxel, cisplatin ? TCF docetaxel, cisplatin, FU 2020/5/9 ECF (epirubicin, cisplatin, infusional 5-FU) is widely used particularly in Europe on the basis of the results of two randomized phase 3 trials and a recent meta-analysis 2020/5/9 1. ECF vs FAMTX Waters JS, et al, Br J Cancer 1999 2020/5/9 Waters JS, et al, Br J Cancer 1999 ECF vs FAMTX 2020/5/9 2. ECF vs MCF Ross P , et al, J Clin Oncol , 2002 2020/5/9 3. ECF vs CF (a meta-analysis ) Wagner AD, et al. J Clin Oncol 2006; 24 2020/5/9 But the a drawback of ECF is the 5-FU infusion requires a central venous indwelling catheter, which is associated with significant morbidity, particularly venous thrombosis and infections. 2020/5/9 EOX vs ECF